Vivos Therapeutics reported Q2 2024 revenue of $4.1 million, a 19% increase from $3.4 million in Q2 2023. Product revenue rose 28% to $2.0 million while service revenue grew 12% to $2.1 million. Net loss improved significantly to $1.9 million compared to $5.5 million in Q2 2023, reflecting successful cost reduction initiatives. Gross margin expanded to 65% from 62% year-over-year.The company strengthened its financial position through strategic initiatives, including a $7.5 million equity investment from V-CO Investors LLC in June 2024. Operating expenses decreased 30% to $4.1 million, driven by reduced professional fees and personnel costs. Cash and cash equivalents stood at $6.9 million as of June 30, 2024.Vivos executed a pivotal strategic alliance agreement with Rebis Health Holdings to expand its marketing and distribution model. The company aims to replicate this model with other healthcare providers to increase revenues. However, management noted that additional financing will be required to fund operations over the next 12 months, raising going concern considerations.

Vivos Therapeutics reported Q2 2024 revenue of $4.1 million, a 19% increase from $3.4 million in Q2 2023. Product revenue rose 28% to $2.0 million while service revenue grew 12% to $2.1 million. Net loss improved significantly to $1.9 million compared to $5.5 million in Q2 2023, reflecting successful cost reduction initiatives. Gross margin expanded to 65% from 62% year-over-year.The company strengthened its financial position through strategic initiatives, including a $7.5 million equity investment from V-CO Investors LLC in June 2024. Operating expenses decreased 30% to $4.1 million, driven by reduced professional fees and personnel costs. Cash and cash equivalents stood at $6.9 million as of June 30, 2024.Vivos executed a pivotal strategic alliance agreement with Rebis Health Holdings to expand its marketing and distribution model. The company aims to replicate this model with other healthcare providers to increase revenues. However, management noted that additional financing will be required to fund operations over the next 12 months, raising going concern considerations.